Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Publication of Raute Corporation’s Q3 2023 Interim Report and invitation to a briefing

Raute Corporation, Investor news, 20 October 2023  Publication of Raute Corporation’s Q3 2023 Interim Report and invitation to a briefing   Raute Corporation will publish its Interim Report for January 1−September 30, 2023 on Thursday, October 26, 2023 at about 8:30 a.m. Finnish time. A briefing for analysts, investors and the media will be organized on the same day October 26, 2023 at 2:00−3:00 p.m.   Venue: Scandic Simonkentta Hotel, Simonkatu 9, Helsinki.   Please inform of your participation in the briefing at the latest on Tuesday, October 24, 2023 to Raute

BioArctic presents Nomination Committee

Stockholm, Sweden, October 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on June 1, 2023, adopted an instruction regarding the appointment of the Nomination Committee. Pursuant to this instruction the company shall have a Nomination Committee comprising one representative for each of the three principal shareholders in terms of votes, based on the information received from Euroclear Sweden AB on the last banking day in September 2023, as well as the Chairman of the Board (convener).September 30, 2023, the three largest shareholders were Demban AB,

Last day of subscription of units in Risk Intelligence A/S ongoing rights issue and guidance on how to subscribe

Risk Intelligence A/S ("Risk Intelligence" or the "Company") announce that Tuesday, 24 October 2023, is the last day for subscription in Risk Intelligences ongoing rights issue of units of approximately DKK 18.4 million (the "Rights Issue").  The last day of trading in unit rights on Spotlight Stock Market is today, the 20 October 2023. Note that some banks and brokers have an earlier date for subscription than the 24 October. Current shareholders or new investors should therefore examine with their bank or broker whether they are using an earlier last day of subscription.There are two

Warrants of series TO2 were subscribed to approximately 1.65 percent and Pharmacolog i Uppsala AB receives approximately SEK 6.6 thousand

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEELAND, RUSSIA, SCHWEIZ, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Pharmacolog i Uppsala AB (publ) ("Pharmacolog" or "the Company") today announces the outcome of the exercise of warrants of series TO2, which were issued in

Arise and SCA cooperate in development of approx. 1,000 MW of wind power

Arise AB (publ) (”Arise”) today entered into a partnership agreement with SCA, Europe’s largest private forest owner, regarding the development of onshore wind power on parts of SCA’s land in Sweden. The development partnership with SCA is another step in Arise’ focus to deepen cooperations with landowners in the company’s core markets with the aim developing and constructing new wind power. Arise and SCA have identified six concrete land areas with an estimated total potential of approximately 1,000 MW. The identified land areas are believed to have good prospects to realize projects on

SCA to build new wind farm and increases the degree of self-sufficiency in electricity

SCA is increasing its degree of self-sufficiency in electricity for its own industry by acquiring Fasikan Vind AB, a wind power project located on SCA's land in the Bräcke municipality of Jämtland County. The seller is Arise AB.  The acquisition is in line with SCA's wind power strategy, which includes leasing land to wind power operators, operating own wind farms, and project development for own operation or for sale.  Construction of the wind farm will begin in November 2023 and is planned to be operational at the beginning of 2026. The wind farm will consist of 15 turbines with

Nomination Committee appointed ahead of the 2024 Annual General Meeting

In accordance with the guidelines adopted by the Annual General Meeting on May 4, 2017, GARO has established a Nomination Committee. The Nomination Committee is to prepare and make proposals to the 2024 Annual General Meeting concerning:  · the Chairman of the Annual General Meeting; · candidates for the post of Chairman and other members of the Board; · election and remuneration of the company’s auditors; · board fees and distribution between the Chairman and other members as well as remuneration for committee work; and · any changes to the instructions for the

Episurf Medical: 510(k) submission for big toe implant today

Episurf Medical (NASDAQ: EPIS B) today announces that a 510(k) filing to the US FDA for market clearance of the company’s toe implant for the 1[st] MTP joint is being submitted today. The submission will now undergo a review process and the company aims to receive clearance to be able to launch the product on the US market during 2024. “This is a significant milestone which we have been looking forward to for quite some time. With this product, we are entering into a fast-moving and fast-growing market segment, with a totally unique solution. This is also the last piece of the puzzle of

BioStock: Ultimovacs reaches proof of concept with UV1 cancer vaccine

Ultimovacs has reported positive phase II overall survival data with its cancer vaccine candidate UV1 in mesothelioma. The data will be presented by the Principal Investigator of the NIPU trial, Professor Åslaug Helland, at the ESMO Congress 2023. BioStock spoke with the the Norwegian biotech’s Director Medical Affairs Espen Basmo Ellingsen to better understand the significance of these results.Read the interview with Espen Basmo Ellingsen at biostock.se: Ultimovacs reaches proof of concept with UV1 cancer vaccine - BioStock 

CEO Johan Forssell will leave Investor in May 2024 in a new role with focus on industrial companies

After nearly 30 years at Investor, of which the last close to nine years as President and CEO, Johan Forssell has informed Investor’s Board of Directors that he wants to transition to a role focusing on board work in industrial companies. This means that Johan Forssell will leave Investor, and its Board, in conjunction with the Annual General Meeting (AGM) on 7 May 2024. Johan Forssell will in his new role, through a consultancy agreement, be assigned to Investor as an industrial advisor with a particular focus on industrial companies. He will work with board assignments and also work in

Breidablikk on stream ahead of schedule

Sandnes, Norway, 20 October: Production from the Breidablikk field in the North Sea commenced on October 19, ahead of plan and on budget. Tied back to the Grane platform, the subsea field holds almost 200 million barrels of recoverable oil. The project supports the company’s strategy for growth and value creation. “We are delighted to see Breidablikk coming on stream four months ahead of plan, within budget and with higher initial production than expected. This marks a key milestone in our strategy for growth and long-term value creation of more than 50% production increase and to reach

The world's first Fairness Receipt

Most credit companies go to absurd lengths to hide their real terms, obscuring the details through impenetrable legal jargon and opaque phrasings. Fairlo is now doing the exact opposite and launches the world' first Fairness Receipt, a detailed breakdown of the deal. Where does the money go, to what and what do we stand to profit? In short, what finance geeks call "unit economics".The Swedish fintech challenger Fairlo believes in a fair world, even when it comes to money, and, that the first step towards a more fair credit industry is transparency. The better informed the customer is, the

Board resolution regarding the repurchase of shares

The Annual General Meeting of Wallenstam AB (publ) on May 3, 2023, resolved to authorize the board to take decisions concerning the acquisition of the company’s own shares up until the next AGM. Today, the Board resolved to use this authorization on the basis of the conditions stipulated by the AGM.Purchase can be made on Nasdaq Stockholm or another regulated market of as many of its own B shares, such that the company’s holding at any one time does not exceed 10 percent of all shares in the company. Such acquisitions shall take place at the best available price for the company. The

Total Voting Rights

BLACKROCK ENERGY AND RESOURCES INCOME TRUST PLC (the “Company”) LEI - 54930040ALEAVPMMDC31 Voting Rights and Capital (Article 15 Transparency Directive, DTR 5.6) In conformity with the FCA's Disclosure Guidance and Transparency Rules ("the Rules"), provision 5.6.1, the Company would like to notify the market that as at 20 October 2023 its issued capital comprised 135,586,194 ordinary shares of £0.01 each, including 3,250,000 shares held in treasury. Shareholders should therefore use 132,336,194 (being the Companies issued share capital excluding shares held in treasury) as the

BioGaia AB: Interim report third quarter January – September 2023

THIRD QUARTER 2023 Figures in parentheses refer to the corresponding period last year, unless otherwise specified. · Net sales amounted to SEK 317.7 million (257.7), an increase of SEK 60.0 million, or 23% (excluding foreign exchange effects, 17%). · Net sales in the Paediatrics segment amounted to SEK 255.8 million (205.7), a change of 24% (excluding foreign exchange effects an increase of 18%). · Net sales in the Adult Health segment amounted to SEK 59.2 million (50.5), an increase of 17% (excluding foreign exchange effects, an increase of 11%). · Operating expenses

Exciting panels at BioStock Life Science Fall Summit!

On October 25&26, the 6th annual  BioStock Life Science Fall Summit takes place live in Lund. Appart from 40+ life science companies presenting, the packed two-day event will be gilded by enlightening expert insights and thrilling panel discussions.What small to mid size life science company is not eager to pick the brains of big pharmas business developers, licensing and partnering experts? What investor within the space does not benefit from discussions on valuation and market trends?  Or wish to learn more of the perspectives of professional venture capitalists?   For more on these

The second part of Dicot's phase 1 study starts today

Press release: Uppsala, Sweden, October 20, 2023. In August, the pharmaceutical company Dicot's phase 1 study was initiated, with single dosing of the participants. Concurrently, the second part of the study starts today, where safety of LIB-01 is now being studied with repeated dosing.Dicot's first clinical study in humans with the potency drug candidate LIB-01 started in August and is in full swing. Initially, participants were administered a single dose, called Single Ascending Dose (SAD). Now, in parallel, the study is moving into next part where new participants receive repeated dosing,

Invitation to presentation of Bactiguard’s interim report for the third quarter 2023

Bactiguard Holding AB (publ) publishes its interim report for the third quarter on Friday October 27, 2023 at 08:00 CEST.In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CEST. Interim CEO Thomas von Koch will present the report and, together with CFO Carin Jakobson, answer questions. The report and a presentation will be available at Bactiguard’s website bactiguard.com  To participate in the audiocast, please use this link:www.bactiguard.com/report/q3-2023/ To

Invitation to a press and analyst conference in Stockholm for presentation of Concentric’s Third Quarter 2023 results

Concentric's Interim Report for Q3 (January-September 2023), will be published on the 8 of November  2023, at 08.00 CET. At 10.00 CET media, investors and analysts are invited to Tändstickspalatset, Västra Trädgårdsgatan 15 in Stockholm, for a presentation of the report. There will also be an opportunity to participate via webcast/telephone conference. President & CEO Martin Kunz and CFO Marcus Whitehouse will host the presentation, which will be held in English and is followed by a Q&A-session. We look forward to your participation. Please see the below detailed information to join

On the edge of turning the profit corner

Interim Report Safeture AB Q3 2023: · Annual recurring revenue (ARR) growth of +26% to 50,3 MSEK. · Recurring revenue amounts to 12,3 MSEK compared to 9,2 MSEK last year (+33%). · EBIT improvement year-on-year of 2,3 MSEK, reaching -0,6 MSEK. · Bottom-line result at -4% of net sales compared to -31% one year ago. · Quarterly churn at 0,5% · Yearly NRR at 113%Classics First nine months (2023-01-01 to 2023-09-30) · Net revenue amounted to 34 182 (26 242) TSEK (+30%). · Loss after financials amounted to -4 639 (-11 816) TSEK. · Loss per share before dilution

Nomination Committee appointed for the Annual General Meeting 2024 in Proact IT Group AB (publ)

According to the decision from the previous Annual General Meeting of Proact IT Group AB a nomination committee has been constituted with the task of preparing proposals to be submitted to the company's Annual General Meeting 2024.The nomination committee is to consist of representatives of the four biggest shareholders. If any of them does not exercise the right to appoint a member, the right to appoint such a member shall pass to the next largest shareholder in terms of voting rights. The nomination committee also has the right to adjunct the board chairman to the election committee’s

Peab rebuilds Värnamo Hospital

Peab has been commissioned to rebuild and add on to Värnamo Hospital. The customer is Regionsfastigheter in Jönköping County and the contract is worth SEK 214 million.The project entails the new construction of Building 21 at Värnamo Hospital. The new building will contain premises for the psychiatric clinic, which will include a ward with 24/7 care, an on-call and addiction clinic, administration offices and personnel rooms. Building 21 will be connected to the existing Building 09 through a new passageway, which will entail rebuilding certain areas in Building 09. The SundaHus Material

Conclusion of independent statement related to the voluntary offer by T-C Storage HoldCo AB for the shares in Self Storage Group ASA

Oslo, 20 October 2023 - Reference is made to the stock exchange announcement made on 20 September 2023 by Self Storage Group ASA (the "Company", OSE: SSG) where the Company jointly announced with T-C Storage HoldCo AB (the "Offeror") an agreement for the Offeror to launch a voluntary cash offer to acquire all of the issued and outstanding shares in the Company (the "Shares") for NOK 40 per Share (the "Offer"), and the announcement on 11 October 2023 regarding commencement of the offer period for the Offer. The Board of Directors of SSG has unanimously resolved that it has recommended the

Wallenstam’s interim report Jan–Sep, 2023: Good position in a turbulent global climate

Hans Wallenstam, CEO, and Susann Linde, CFO and Head of Investor Relations, comment on the report at www.wallenstam.se/filmsandpresentations. The film will be released by 08.30 (CEST) at the latest. An audiocast in English with Susann Linde will take place at 09.00 (CEST) at www.financialhearings.com. The presentation is available at www.wallenstam.se/filmsandpresentations before 09.00 (CEST). January 1–September 30, 2023 · The equity/assets ratio amounted to 46 percent and the loan-to-value ratio was 46 percent. · Investment in construction of properties amounted to SEK 1,861

There are no items matching the current filter
There are no more items matching the current filter
Back to top